Extract SBIR Proposal Intelligence via FOIA Data Harvest
- Organization
- National Science Foundation (NSF)
- Sector
- SBIR Phase I awardees seeking Phase II funding
- Location
- United States
Source reference
Executive summary
Current state
NSF awarded $305K SBIR Phase I funding to ENDURE BIOTHERAPEUTICS for a precision microbiome therapeutic platform targeting PKU, creating a structural 6-month funding cliff and commercial execution gap despite government validation of the technology.
Market catalyst
NSF SBIR proposals and reviewer comments are subject to FOIA disclosure, creating a public intelligence goldmine on ENDURE's technical approach, weaknesses, and commercialization plans that they assume remain confidential between them and NSF.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.